Towards a more patient-centric assessment of immunogenicity for low-risk biologics in immuno-oncology clinical trials

Mohamed Hassanein; Ying Wang; Donghua Yin; Daniel Baltrukonis

doi:10.4155/bio-2021-0169

Towards a more patient-centric assessment of immunogenicity for low-risk biologics in immuno-oncology clinical trials

Bioanalysis. 2021 Sep;13(17):1309-1312. doi: 10.4155/bio-2021-0169. Epub 2021 Sep 2.

Authors

Mohamed Hassanein¹, Ying Wang², Donghua Yin³, Daniel Baltrukonis¹

Affiliations

¹ Clinical Assay Group, Global Product Development (GPD), Pfizer Inc., Groton, CT 06340, USA.
² BioMedicine Design, Pfizer Inc., Andover, MA 01810, USA.
³ Clinical Pharmacology, Early Clinical Development, Pfizer Inc., San Diego, CA 92121, USA.

PMID: 34470480
DOI: 10.4155/bio-2021-0169

No abstract available

Keywords: IO; biotherapeutic; clinical impact; immunogenicity; immunotherapies; incidence of antidrug antibodies; monoclonal antibodies; neutralizing antibodies; reporting.

Publication types

Editorial

MeSH terms

Biological Products / therapeutic use*
Clinical Trials as Topic
Humans
Neoplasms / drug therapy*
Patient-Centered Care / methods*

Substances

Biological Products